Forum Snooker Championship GOLD 2006 Strona Główna
»
Zapisy
Napisz odpowiedź
Użytkownik
Temat
Treść wiadomości
Emotikony
Więcej Ikon
Kolor:
Domyślny
Ciemnoczerwony
Czerwony
Pomarańćzowy
Brązowy
Żółty
Zielony
Oliwkowy
Błękitny
Niebieski
Ciemnoniebieski
Purpurowy
Fioletowy
Biały
Czarny
Rozmiar:
Minimalny
Mały
Normalny
Duży
Ogromny
Zamknij Tagi
Opcje
HTML:
NIE
BBCode
:
TAK
Uśmieszki:
TAK
Wyłącz BBCode w tym poście
Wyłącz Uśmieszki w tym poście
Kod potwierdzający: *
Wszystkie czasy w strefie EET (Europa)
Skocz do:
Wybierz forum
Snooker Championship GOLD 2005
----------------
Zapisy
Wyniki
Pytania
Offtopic
Przegląd tematu
Autor
Wiadomość
quit_smoking
Wysłany: Pon 16:13, 26 Gru 2005
Temat postu: Still smoking? This help you to quit!
History
bupropion
was first synthesized by Burroughs Research in 1966, and patented by Burroughs-Wellcome (later Glaxo-Wellcome, and, as of 2000, GlaxoSmithKline) in 1974. It was approved by the
FDA
in 1985 and marketed under the name
Wellbutrin
as an antidepressant, but clinical trials indicated that incidence of seizure was two to four times greater than other antidepressants and the drug was quickly pulled from the market. Glaxo, realizing that seizure risk was a function of dosage, then developed and marketed a sustained-release (SR) version of
Wellbutrin
which, when ingested, releases
bupropion
hydrochloride at a constant, gradual rate into the body. Because of this altered mechanism of delivery, incidence of seizure with
Wellbutrin
.buy.blogopt.com]
Wellbutrin
-SR[/url] is comparable to, and in some cases, lower than that of other antidepressants.
In 1997,
bupropion
HCl was approved by the FDA for use as a smoking cessation aid. Because the name
Wellbutrin
was still associated with high seizure risk, Glaxo subsequently marketed the drug under the name
Zyban
to help people
stop smoking tobacco
by reducing the severity of withdrawal symptoms. It can be used in combination with nicotine replacement therapies.
bupropion
treatment course lasts for seven to twelve weeks, with the patient halting the use of tobacco around ten days into the course.
Mode of action
bupropion
is a selective catecholamine (norepinephrine and dopamine) reuptake inhibitor. It has only a small effect on serotonin reuptake. It does not inhibit MAO. The actual mechanism behind
bupropion
\'s action is not known, but it is thought to be due to the effects on dopaminergic and noradrenergic mechanisms.
Pharmacokinetics
bupropion
is metabolised in the liver. It has at least three active metabolites: hydroxy
bupropion
, threohydro
bupropion
and erythrohydro
bupropion
. These active metabolites are further metabolised to inactive metabolites and eliminated through excretion into the urine. The half-life of
bupropion
is 20 hours as is hydroxy
bupropion
\'s. Threohydro
bupropion
\'s half-life is 37 hours and erythrohydro
bupropion
\'s 33 hours.
Chronic hepatotoxicity in animals
In rats receiving large doses of
bupropion
chronically, there was an increase in incidence of hepatic hyperplastic nodules and hepatocellular hypertrophy. In dogs receiving large doses of
bupropion
chronically, various histologic changes were seen in the liver, and laboratory tests suggesting mild hepatocellular injury were noted.
Indications
management of depression
adjunctive in tobacco withdrawal
attention deficit disorder
Contraindications
epilepsy and other conditions that lower the seizure-threshold (alcohol withdrawal, active brain tumors etc.)
concomitant treatment with MAO-Inhibitors
caution with the concomitant use of sympathomimetic drugs (e.g. Ephedrine)
active liver damage (e.g. cirrhosis)
anorexia, bulimia
severe kidney disease
severe hypertension
anxiety disorders (caution), agitated patients
pediatric patients (see below)
use considerable caution in treating patients where suicide may be a risk
Interactions
Quite a great number of drugs show clinically significant interactions with
bupropion
. Study the packing insert carefully and ask your prescribing physician in any case of doubt.
Abuse liability
In animal studies and small studies with persons having experience with the use of
amphetamines
or
cocaine
,
bupropion
caused drug-seeking behaviour (animal experiments) and was recognized as an amphetamine-like drug by the humans. In a scale ranging from
placebo
on the lower side to benzedrine, it was given an intermediate score indicating moderate likelihood of abuse. In clinical practise,
bupropion
has been shown that the dose required for significant abuse would cause seizures in most patients. Abuse has not become a significant problem in clinical usage, but the drug should be given with caution to patients with a history of drug or alcohol abuse or dependence.
bupropion
is not a controlled substance.
Limitation to tobacco withdrawal
In some countries
bupropion
is approved only as a smoking cessation aid and not for treatment of depression.
Influence on sexual function/
libido
An advantage of
bupropion
over most conventional antidepressants is that it causes no sexual dysfunction in men and may even increase
libido
. According to a recent study,
bupropion
does also increase
libido
in women with \"hypoactive sexual desire disorder\" but without signs of depression. It is too early to come to conclusive evidence whether to treat these women or not. Further controlled studies are required.
Solaris phpBB theme/template by Jakob Persson
Copyright © Jakob Persson 2003
fora.pl
- załóż własne forum dyskusyjne za darmo
Powered by
phpBB
© 2001, 2002 phpBB Group
Regulamin